{"nctId":"NCT00175019","briefTitle":"Allopurinol Versus Febuxostat in Subjects Completing the Phase 3 Trials C02-009 or C02-010","startDateStruct":{"date":"2003-07"},"conditions":["Gout"],"count":1086,"armGroups":[{"label":"Febuxostat 80 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Febuxostat 120 mg QD","type":"EXPERIMENTAL","interventionNames":["Drug: Febuxostat"]},{"label":"Allopurinol QD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Allopurinol"]}],"interventions":[{"name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"name":"Febuxostat","otherNames":["TMX-67","Tei-6720","Uloric"]},{"name":"Allopurinol","otherNames":["Zyloprim"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is receiving thiazide diuretic therapy (only to subjects randomized to or receiving febuxostat).\n* Has a serum urate level less than 8.0 mg/dL and is not taking uric acid-lowering therapy (other than allopurinol or febuxostat).\n* Has participated in a clinical study in which febuxostat was administered.\n* Is completing Phase 3 Studies C02-009 or C02-010.\n* Must not have experienced any serious study drug-related adverse events in the previous study.\n* Females of childbearing potential who are sexually active must agree to use adequate contraception, and can neither be pregnant nor lactating from Screening throughout the duration of the study\n\nExclusion Criteria:\n\n* Has had any other significant medical condition as defined by the investigator that would interfere with the treatment, safety, or compliance with the protocol.\n* Is intolerant of allopurinol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"SECONDARY","title":"Percent Change in Serum Urate Levels From Baseline to the Last Visit on Treatment.","description":"The percent change in serum urate from baseline to the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-46.69","spread":"17.43"},{"groupId":"OG001","value":"-52.99","spread":"19.12"},{"groupId":"OG002","value":"-32.17","spread":"17.71"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Primary Tophus Size at Month 12 for Subjects With Palpable Tophi Measured at Baseline.","description":"The area of the primary tophus was calculated based on the length and width of the tophus measured at the Month 12 visit. The percent change from baseline in primary tophus size to the Month 12 visit was summarized.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-82","spread":null},{"groupId":"OG001","value":"-79","spread":null},{"groupId":"OG002","value":"-56","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 1.","description":"Serum urate values were obtained at the Month 1 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 1 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":null},{"groupId":"OG001","value":"87.0","spread":null},{"groupId":"OG002","value":"46.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 12.","description":"Serum urate values were obtained at the Month 12 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 12 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.9","spread":null},{"groupId":"OG001","value":"86.3","spread":null},{"groupId":"OG002","value":"82.2","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 24.","description":"Serum urate values were obtained at the Month 24 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 24 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89.3","spread":null},{"groupId":"OG001","value":"87.2","spread":null},{"groupId":"OG002","value":"78.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Month 36.","description":"Serum urate values were obtained at the Month 36 visit. The percentage of subjects whose serum urate was \\<6.0 mg/dL at the Month 36 visit was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"90.8","spread":null},{"groupId":"OG001","value":"91.5","spread":null},{"groupId":"OG002","value":"90.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Subjects Whose Serum Urate Level Decreases to < 6.0 mg/dL at Last Visit on Treatment.","description":"The percentage of subjects whose serum urate was \\<6.0 mg/dL at the last visit on treatment was summarized. The last visit on treatment was the last visit at which a serum urate value was collected prior to any changes in drug and/or dose from the initial treatment assignment.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null},{"groupId":"OG001","value":"82.0","spread":null},{"groupId":"OG002","value":"32.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Primary Tophus Size at Month 24 for Subjects With Palpable Tophi Measured at Baseline.","description":"The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 24 visit. The percent change from baseline in primary tophus size to the Month 24 visit was summarized.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-100","spread":null},{"groupId":"OG001","value":"-96","spread":null},{"groupId":"OG002","value":"-87","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Primary Tophus Size at Month 36 for Subjects With Palpable Tophi Measured at Baseline.","description":"The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and Month 36 visit. The percent change from baseline in primary tophus size to the Month 36 visit was summarized.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-83","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Primary Tophus Size at Final Visit for Subjects With Palpable Tophi Measured at Baseline.","description":"The area of the primary tophus was calculated based on the length and width of the tophus measured at baseline and final visit. The percent change from baseline in primary tophus size to the final visit was summarized.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-96","spread":null},{"groupId":"OG001","value":"-84","spread":null},{"groupId":"OG002","value":"-67","spread":null}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in the Total Number of Tophi for Subjects With Palpable Tophi at Final Visit.","description":"The number of tophi were counted at baseline and final visits. The percent change from baseline in the number of tophi to the final visit was summarized.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-59.9","spread":"45.9"},{"groupId":"OG001","value":"-58.3","spread":"42.5"},{"groupId":"OG002","value":"-48.7","spread":"42.5"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Requiring Treatment for Gout Flare up to Month 12.","description":"The percentage of subjects requiring treatment for gout flare during the first twelve months of final stable treatment was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.4","spread":null},{"groupId":"OG001","value":"42.5","spread":null},{"groupId":"OG002","value":"28.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Requiring Treatment for Gout Flare After Month 12.","description":"The percentage of subjects requiring treatment for gout flare after the first 12 months of final stable treatment was summarized.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":null},{"groupId":"OG001","value":"19.8","spread":null},{"groupId":"OG002","value":"23.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":98,"n":801},"commonTop":["Upper Respiratory Tract Infections","Musculoskeletal and Connective Tissues Signs and Symptoms NEC","Joint Related Signs and Symptoms","Vascular Hypertensive Disorders NEC","Lower Respiratory Tract and Lung Infections"]}}}